Clinicopathological value of tumor-associated macrophages in adult classical Hodgkin lymphoma in Hawler city
DOI:
https://doi.org/10.15218/zjms.2025.012Keywords:
CD68, Classical Hodgkin’s lymphoma (cHL), Tumor associated macrophage (TAM)Abstract
Background and objective: The aims of the present research were to study the clinicopathological features of adult classical Hodgkin lymphoma (cHL) in Hawler city and to evaluate the significance of immunohistochemical expression of CD68 positive tumor associated macrophage in the tumor microenvironment as a marker for prediction of malignant progression.
Methods: This is a retrospective cross-sectional study carried out in Rizgary Teaching Hospital and Nanakaly Hospital in Hawler city –Iraq in which 110cases of cHL patients were enrolled from January 2015 to July 2022.Clinical data were obtained from the hospital’s medical records. All specimens were revised for histopathological and immunohistochemical diagnosis of CD15 and CD30 followed by staining with CD68 using IHC.
Results: The IHC showed 56.36% of cases expressed intermediate staining score for CD68 immune marker whereas 27.27% expressed high staining score. A positive association was found between staging of the cases and CD68 immune expressions.
Conclusion: Positive CD68by immunohistochemical analysis on TAM have diagnostic significance, its overexpression may predict cancer progression.
Metrics
References
Takahara T, Satou A, Tsuzuki T, Nakamura S. Hodgkin Lymphoma: Biology and Differential Diagnostic Problem. Diagnostics. 2022; 12(6):1-23. DOI:10.3390/diagnostics12061507.
Pu Y, Ji Q. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. Front Immunol. 2022; 13:1-13. DOI:10.3389/fimmu.2022.874589
Casagrande N, Borghese C, Aldinucci D. Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma. Cancers (Basel). 2022; 14(10):1-25. DOI:10.3390/cancers14102427
Czarkowski M. Helsinki Declaration--next version. Pol Merkur Lek organ Pol Tow Lek. 2014; 36(215):295-7.
Abd Allah MYY, Fahmi MW, EL-Ashwah S. Clinico-pathological significance of immunohistochemically marked tumor-associated macrophage in classic Hodgkin lymphoma. J Egypt Natl Canc Inst. 2020; 32(1):1-9. DOI:10.1186/s43046-020-00029-1
Werner L, Dreyer JH, Hartmann D, Barros MH, Büttner-Herold M, Grittner U, et al. Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome. Sci Rep. 2020; 10(1):1-11. DOI:10.1038/s41598-020-66010-z
Cencini E, Fabbri A, Rigacci L, LazziS, Gini G, Cox MC, et al. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET assessment. Hematol Oncol. 2017; 35(1):69-78. DOI:10.1002/hon.2249
Stein H, Pileri SA, Weiss LM, Poppema S, Gascoyne RO. JES. Hodgkin Lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H TJ, ed. World Health Organization Classification of Tumours Vol 3. 4th ed. Lyon; 2015:423-41.
Satou A, Takahara T, Nakamura S. An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Cancers (Basel). 2022;14(11):1-17. DOI:10.3390/cancers14112647.
Bienz M, SalimaRamdani S, Knecht H. Molecular Pathogenesis of Hodgkin Lymphoma: Past, Present, Future. Int J Mol Sci. 2020; 21: 6623. DOI:10.3390/ijms21186623.
Mohamed O, El Bastawisy A, Allahlobi N, Abdellateif MS, Zekri AR, Shaarawy S, et al. The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. Diagn Pathol. 2020; 15(1):1-13. DOI: 10.1186/s13000-019-0912-3
Karihtala K, Leivonen SK, Brück O, Karjalainen-Lindsberg ML, Mustjoki S, Pellinen T, et al. Prognostic impact of tumor-associated macrophages on survival is checkpoint dependent in classical hodgkin lymphoma. Cancers (Basel). 2020; 12(4):1-15. DOI:10.3390/cancers12040877
Mohammedzaki LB, Hasan KM. Clinicopathological, immunohistochemical charachtaristic and the outcome of Hodghkin lymphoma patients in Erbil city , Iraq. Iraqi J Hematol. 2019; 8(1):14-20. DOI:10.4103/ijh.ijh
James O, Armitage JWF. Clinical Evaluation. In: Andreas Engert AY, ed. Hodgkin Lymphoma A Comprehensive Overview. 3rded. USA:Springer; 2020. P. 99-111.
Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016; 54:17-24. DOI:10.1016/j.humpath.2016.03.005.
Guo B, Cen H, Tan X, Qing K. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Medicine. 2016; 14:159. DOI 10.1186/s12916-016-0711-6.
Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017. DOI 10.1182/blood-2017-06- 781989.
Roemer MGM, Redd RA, Cader FZ, Pak CH, Abdelrahman S, Ouyang J, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018; 36(10):942-50. DOI:10.1200/JCO.2017.77.3994
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tenya Tariq Abdulhameed, Salah Abubakir Ali, Amin Aziz Bakir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
